CardiaTec

CardiaTec iapplies artificial intelligence to large-scale multi-omic data for the development of next-generation drug targets for cardiovascular diseases. Recognizing cardiovascular disease as a leading global cause of death, CardiaTec emphasizes a biology-first approach in drug discovery, enabling computationally driven target-drug interactions. The company aims to enhance personalized medicine by exploring patient stratification and biomarker identification, ensuring that novel therapeutics are tailored to specific patient endotypes. This strategy seeks to improve patient outcomes and transition away from traditional one-size-fits-all treatment methods.

‍